Skip to main content

PAPEL DE LOS FACTORES DE RESPUESTA A OXIGENO HIF EN PATOLOGIA PULMONAR Y BIOMARCADORES DIAGNOSTICO/PRONOSTICO NO INVASIVOS EN ENFERMEDAD RESPIRATORIA

SAF2013-46058-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hypoxia-inducible factor 2-dependent pathways driving Von Hippel–Lindau-deficient renal cancer

  • Meléndez-Rodríguez, Florinda
  • Roche, Olga
  • Sánchez-Prieto, Ricardo
  • Aragonés, Julián
The most common type of the renal cancers detected in humans is clear cell renal cell carcinomas (ccRCCs). These tumors are usually initiated by biallelic gene inactivation of the Von Hippel–Lindau (VHL) factor in the renal epithelium, which deregulates the hypoxia-inducible factors (HIFs) HIF1α and HIF2α, and provokes their constitutive activation irrespective of the cellular oxygen availability. While HIF1α can act as a ccRCC tumor suppressor, HIF2α has emerged as the key HIF isoform that is essential for ccRCC tumor progression. Indeed, preclinical and clinical data have shown that pharmacological inhibitors of HIF2α can efficiently combat ccRCC growth. In this review, we discuss the molecular basis underlying the oncogenic potential of HIF2α in ccRCC by focusing on those pathways primarily controlled by HIF2α that are thought to influence the progression of these tumors., This work was supported by grants from Ministerio de Educación y Ciencia (SAF2013-46058-R; SAF2016-76815), TV3 Marató (534/C/2016), and CIBERCV. OR has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla La Mancha (UCLM)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Role of Mitochondrial Complex IV in Age-Dependent Obesity

  • Soro-Arnaiz, I.
  • Li, Q.O.Y.
  • Torres-Capelli, M.
  • Meléndez-Rodríguez, F.
  • Veiga, S.
  • Veys, K.
  • Sebastian, D.
  • Elorza, A.
  • Tello, D.
  • Hernansanz-Agustín, P.
  • Cogliati, S.
  • Moreno-Navarrete, J.
  • Balsa, E.
  • Fuertes, E.
  • Romanos, E.
  • Martínez-Ruiz, A.
  • Enriquez, J.A.
  • Fernandez-Real, J.
  • Zorzano, A.
  • De Bock, K.
  • Aragonés, J.
Aging is associated with progressive white adipose tissue (WAT) enlargement initiated early in life, but the molecular mechanisms involved remain unknown. Here we show that mitochondrial complex IV (CIV) activity and assembly are already repressed in white adipocytes of middle-aged mice and involve a HIF1A-dependent decline of essential CIV components such as COX5B. At the molecular level, HIF1A binds to the Cox5b proximal promoter and represses its expression. Silencing of Cox5b decreased fatty acid oxidation and promoted intracellular lipid accumulation. Moreover, local in vivo Cox5b silencing in WAT of young mice increased the size of adipocytes, whereas restoration of COX5B expression in aging mice counteracted adipocyte enlargement. An age-dependent reduction in COX5B gene expression was also found in human visceral adipose tissue. Collectively, our findings establish a pivotal role for CIV dysfunction in progressive white adipocyte enlargement during aging, which can be restored to alleviate age-dependent WAT expansion.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia, between bench and bedside

  • Cabrera-Fuentes, H. A.|||0000-0002-8502-7098
  • Alba-Alba, Corina
  • Aragones, Julian
  • Bernhagen, Jürgen
  • Boisvert, William A.
  • Bøtker, Hans Erik|||0000-0001-6358-8962
  • Cesarman-Maus, Gabriela
  • Fleming, Ingrid
  • García-Dorado, David|||0000-0002-1126-1279
  • Lecour, Sandrine|||0000-0003-1942-8974
  • Liehn, Elisa
  • Marber, Michael S.
  • Marina, Nephtali
  • Mayr, Manuel
  • Perez-Mendez, Oscar
  • Miura, Tetsuji|||0000-0001-5024-7085
  • Ruiz Meana, Marisol|||0000-0002-4067-4638
  • Salinas-Estefanon, Eduardo M.
  • Ong, Sang-Bing
  • Schnittler, Hans J.
  • Sanchez-Vega, Jose T.
  • Sumoza-Toledo, Adriana
  • Vogel, Carl-Wilhelm
  • Yarullina, Dina
  • Yellon, Derek|||0000-0001-7791-9320
  • Preissner, Klaus T.
  • Hausenloy, Derek J.
Recent advances in basic cardiovascular research as well as their translation into the clinical situation were the focus at the last "New Frontiers in Cardiovascular Research meeting". Major topics included the characterization of new targets and procedures in cardioprotection, deciphering new players and inflammatory mechanisms in ischemic heart disease as well as uncovering microRNAs and other biomarkers as versatile and possibly causal factors in cardiovascular pathogenesis. Although a number of pathological situations such as ischemia-reperfusion injury or atherosclerosis can be simulated and manipulated in diverse animal models, also to challenge new drugs for intervention, patient studies are the ultimate litmus test to obtain unequivocal information about the validity of biomedical concepts and their application in the clinics. Thus, the open and bidirectional exchange between bench and bedside is crucial to advance the field of ischemic heart disease with a particular emphasis of understanding long-lasting approaches in cardioprotection.